• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $FIGS

    FIGS Inc.

    Subscribe to $FIGS
    $FIGS
    Apparel
    Consumer Discretionary

    FIGS, Inc. operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States. It designs and sells healthcare apparel and other non-scrub offerings, such as lab coats, under scrubs, outerwear, activewear, loungewear, compression socks footwear, masks, and face shields. The company markets and sells its products through its digital platform comprising website and mobile app. FIGS, Inc. was founded in 2013 and is headquartered in Santa Monica, California.

    IPO Year: 2021

    Exchange: NYSE

    Website: wearfigs.com

    Recent Analyst Ratings for FIGS Inc.

    DatePrice TargetRatingAnalyst
    5/5/2025$7.00 → $5.00Market Perform
    Telsey Advisory Group
    8/9/2024$6.00 → $7.00Market Perform
    Telsey Advisory Group
    4/2/2024$8.50 → $4.50Neutral → Underperform
    BofA Securities
    3/8/2024Outperform → Perform
    Oppenheimer
    2/29/2024$6.00Outperform → Market Perform
    Telsey Advisory Group
    1/24/2024$7.00Underweight → Equal Weight
    Barclays
    7/17/2023Outperform → Mkt Perform
    Raymond James
    5/3/2023$9.00Buy
    ROTH MKM
    5/2/2023Equal Weight → Underweight
    Barclays
    11/11/2022$12.00 → $8.00Strong Buy → Outperform
    Raymond James
    See more ratings